Burgos MM, Grande RG, Ortega SL, Leiva IS, Lombardo JDLC, Santoyo JS, Perez MJ. Impact of HCV Treatment on Recurrence of Hepatocarcinoma After Liver Transplantation.
Transplant Proc 2023;
55:197-198. [PMID:
36707364 DOI:
10.1016/j.transproceed.2022.12.011]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Accepted: 12/07/2022] [Indexed: 01/26/2023]
Abstract
The treatment of hepatitis C virus (HCV) has been a revolution in hepatology. Since the beginning of transplantation, liver cirrhosis and hepatocarcinoma on HCV cirrhosis has been the main etiology of liver transplantation. We set out to analyze the impact that C virus treatment has had on liver transplantation. To do so, we divided our cohort into 2 periods, one before virus treatment (from 2000-2014) and one after the onset of treatment (2014-2020). Taking into account this differentiation, we analyzed the percentage of patients transplanted for hepatocarcinoma over cirrhotic liver by HCV in both groups. Among the patients transplanted for HCV, we analyzed whether there were differences in hepatocarcinoma recurrences according to their serologic status at the time of transplantation.
Collapse